<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161951</url>
  </required_header>
  <id_info>
    <org_study_id>RRPCEM_NMAT</org_study_id>
    <nct_id>NCT03161951</nct_id>
  </id_info>
  <brief_title>Differential Diagnostics of Etiology of Acute Infections</brief_title>
  <official_title>Differential Diagnostics of Etiology of Acute Infections Based on the Analysis of Expression of Activation Markers on the Surface of Peripheral Blood Monocytes and Neutrophils.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Republican Research and Practical Center for Epidemiology and Microbiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Republican Research and Practical Center for Epidemiology and Microbiology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Method for diagnostics of the origin of infections (bacterial vs viral) based on the&#xD;
      identification of activation markers of blood neutrophils and monocytes will be developed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the study, method for diagnostics of the origin of infections (bacterial vs viral)&#xD;
      based on the identification of activation markers of blood neutrophils and monocytes will be&#xD;
      developed.This method will allow to make a diagnosis within an hour after blood sampling.&#xD;
&#xD;
      The expression of the following markers of activation will be studied using flow cytometry:&#xD;
      CD11b, CD11c, CD13, CD16, CD32, CD35, CD38, CD62L, CD64, CD66b, CD88, CD284, HLA-ABC and&#xD;
      HLA-DR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2017</start_date>
  <completion_date type="Actual">December 29, 2018</completion_date>
  <primary_completion_date type="Actual">December 10, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the diagnosis of bacterial vs viral acute infection</measure>
    <time_frame>1 month</time_frame>
    <description>Sensitivity of the diagnosis of bacterial vs viral acute infection using proposed method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of the diagnosis of bacterial vs viral acute infection</measure>
    <time_frame>1 month</time_frame>
    <description>Specificity of the diagnosis of bacterial vs viral acute infection using proposed method</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">169</enrollment>
  <condition>Intestinal Infectious Diseases</condition>
  <condition>Neuroinfections</condition>
  <arm_group>
    <arm_group_label>Neuroinfections</arm_group_label>
    <description>Patients with acute neuroinfections of bacterial and viral ethology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intestinal Infectious Diseases</arm_group_label>
    <description>Patients with acute intestinal infectious diseases of bacterial and viral ethology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Control group of healthy persons</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the infectious departments of city hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  neuroinfections or acute intestinal infections;&#xD;
&#xD;
          -  the possibility of blood sampling within a period of up to 24 hours from the moment of&#xD;
             admission to hospital;&#xD;
&#xD;
          -  less than 72 hours passed after the onset of the disease and until blood was&#xD;
             collected;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refuse of patient to participate in the trial;&#xD;
&#xD;
          -  more than 24 hours passed after the patient entered the hospital;&#xD;
&#xD;
          -  the disease began more than 72 hours ago;&#xD;
&#xD;
          -  concomitant severe acute and chronic diseases;&#xD;
&#xD;
          -  malignant neoplasms, treatment at a time of less than 1 year, autoimmune diseases in&#xD;
             the phase of exacerbation;&#xD;
&#xD;
          -  pregnancy/lactation;&#xD;
&#xD;
          -  HIV, Hepatites B/C;&#xD;
&#xD;
          -  active tuberculosis;&#xD;
&#xD;
          -  alcohol use disorder/drug addiction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Y Hancharou, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Head of the Laboratory for Immunology and Cellular Biotechnology, The Republican Research and Practical Center for Epidemiology and Microbiology</affiliation>
  </overall_official>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Republican Research and Practical Center for Epidemiology and Microbiology</investigator_affiliation>
    <investigator_full_name>Andrei Y. Hancharou</investigator_full_name>
    <investigator_title>Head of the Laboratory for Immunology and Cellular Biotechnology,</investigator_title>
  </responsible_party>
  <keyword>acute Infections, flow cytometry, cell activation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

